Responses
Rheumatoid arthritis
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.